Beyond Exposure: Standardizing Buprenorphine Training in Pain Medicine Fellowship

The American medical landscape is currently defined by a profound paradox. While the ongoing opioid crisis, characterized by a rise in synthetic illicit opioids continues to ravage communities, our primary pharmacological defense for both opioid use disorder (OUD) and chronic pain management remains underutilized in the very training programs designed to produce “experts” in the field. Pain medicine fellowship training frequently emphasizes the technical mastery of interventional procedures and non-opioid pharmacologic strategies. While these approaches are critically important, education in medication-assisted treatment (MAT), particularly the use of buprenorphine for OUD and complex chronic pain, often receives limited attention. The transition from the restrictive “X-waiver” era to the current regulatory environment was intended to expand and democratize access to buprenorphine treatment. However, legislative change alone cannot substitute for structured clinical education. Removing regulatory barriers does little to improve access if clinicians lack the knowledge, confidence, and training necessary to prescribe and manage these medications effectively. As the opioid crisis persists, it is critical that buprenorphine education be standardized as a core competency within pain medicine fellowship programs. Future pain specialists should be as comfortable initiating and managing buprenorphine therapy as they are performing advanced interventional procedures such as spinal cord stimulation. Strengthening training in this area will better equip pain physicians to address both chronic pain and opioid use disorder within an evolving and increasingly complex public health landscape.